Breaking: FDA to request Sarepta halt shipments of Duchenne therapy

The move, following a series of deaths tied to the company's treatments, is a huge blow to patient community.

Log In    Subscribe BREAKING NEWS   FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy By Jason Mast and Adam Feuerstein Kristoffer Tripplaar/Sipa via AP The Food and Drug Administration will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, according to a source familiar with the matter.   The move follows the death of two teenagers who were administered the treatment, as well as the death of a 51-year-old man who received a similar product in a clinical trial for a different form of muscular dystrophy.  READ MORE Sign up for Daily Recap All the health and medical news you need today, in one email. Learn more. In Case You Missed It 1   Patient dies in Sarepta gene therapy trial, adding to safety concerns By Jason Mast 2   Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move By Jason Mast and Adam Feuerstein 3   After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry By Adam Feuerstein and Jason Mast 4   FDA rejects Capricor's cell therapy for Duchenne muscular dystrophy By Adam Feuerstein Don't miss out on another STAT investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us